ImmunoGen, Inc. Announces Webcast of its Analyst and Investor Event on September 18, 2015
August 20 2015 - 4:15PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that investors,
journalists and the general public are invited to listen to a live
webcast of the Company’s analyst and investor community meeting on
September 18, 2015.
The event will focus on ImmunoGen’s strong foundation for
growth, including the advancement of its multi-product pipeline,
its proprietary technology that is enabling the development of
novel anticancer therapies and the Company’s core competencies that
position it for success.
The video webcast will begin at 8:30 a.m. ET and will be
accessible through the Investors section of the Company’s website,
www.immunogen.com. The meeting is expected to last approximately
three hours, including a short break. An archive of the webcast
will be available on the Company’s website through October 2,
2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells. The
Company utilizes its ADC technology with its antibodies to create
ImmunoGen product candidates and also out-licenses limited rights
to use its technology to other companies. Roche’s Kadcyla® is the
first marketed product with ImmunoGen’s ADC technology. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150820006194/en/
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024